LS mean (SE) % change from baseline in
calculated LDL-c at week 24
Greater LDL-C reduction with alirocumab
than with conventional intensive lipidlowering strategies in ODYSSEY OPTIONS I
%
alirocumab
add-on
ezetimibe
add-on
doubling
ATV dose
switch to
rosuvastatin
0
-10
-20
-30
-40
-50
-60
-70
entry statin: atorvastatin 20 mg
entry statin: atorvastatin 40 mg
Adapted from: Bays et al., J Clin Endocrinol Metab. 2015